Instem Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Instem hat ein Gesamteigenkapital von £54.6M und eine Gesamtverschuldung von £1.0M, wodurch sich der Verschuldungsgrad auf 1.9% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen £83.7M bzw. £29.0M. Instem Das EBIT des Unternehmens beträgt £6.3M, so dass der Zinsdeckungsgrad 20.5 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von £8.4M.

Wichtige Informationen

1.9%

Verhältnis von Schulden zu Eigenkapital

UK£1.03m

Verschuldung

Zinsdeckungsgrad	20.5x
Bargeld	UK£8.44m
Eigenkapital	UK£54.64m
Gesamtverbindlichkeiten	UK£29.01m
Gesamtvermögen	UK£83.65m

Jüngste Berichte zur Finanzlage

Recent updates

Is Instem plc's (LON:INS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Mar 03

Shareholders Are Thrilled That The Instem (LON:INS) Share Price Increased 190%

Jan 29

Calculating The Intrinsic Value Of Instem plc (LON:INS)

Dec 25

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: INSDie kurzfristigen Aktiva des Unternehmens (£24.2M) decken seine kurzfristigen Passiva (£25.5M) nicht.

Langfristige Verbindlichkeiten: INSDie kurzfristigen Vermögenswerte des Unternehmens (£24.2M) übersteigen seine langfristigen Verbindlichkeiten (£3.5M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: INS über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: INSDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 1.9% gestiegen.

Schuldendeckung: INSDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (819.6%).

Zinsdeckung: Die Zinszahlungen für die Schulden von INS sind durch das EBIT gut gedeckt (20.5x coverage).

Instem Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Instem's Shares to Trading on AIM Expected to Be Cancelled on 21 November 2023

Recent updates

Instem Enables Clients to Leverage ICH S1B Weight of Evidence Guideline

ArchiMed SAS agreed completed the acquisition of Instem plc (AIM : INS) from group of sellers.

ArchiMed SAS agreed completed the acquisition of Instem plc (AIM : INS) from group of sellers.

Instem's Shares to Trading on AIM Expected to Be Cancelled on 21 November 2023

Here's Why We Think Instem (LON:INS) Might Deserve Your Attention Today

New minor risk - Earnings quality

ArchiMed SAS agreed to acquire Instem plc (AIM : INS) from group of sellers for approximately £190 million.

ArchiMed SAS agreed to acquire Instem plc (AIM : INS) from group of sellers for approximately £190 million.

An Intrinsic Calculation For Instem plc (LON:INS) Suggests It's 29% Undervalued

Less than half of directors are independent

Instem plc, Annual General Meeting, Jun 27, 2023

Ennov SA acquired Samarind Ltd from Instem plc (AIM:INS).

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Instem plc Announces Board and Committee Appointments

CEO & Executive Director exercised options and sold UK£143k worth of stock

Price target increased to UK£10.10

Less than half of directors are independent

Instem Unveils New Additions to Its Leading Computational Toxicology Software Suite

First half 2022 earnings released: EPS: UK£0.057 (vs UK£0.048 in 1H 2021)

Instem plc Announces Settlement of Historical Licence Dispute

Instem plc to Report First Half, 2022 Results on Sep 27, 2022

Instem plc, Annual General Meeting, Jun 09, 2022

European Medicines Agency Awards Research Grant to Instem

Instem plc Receives European Medicines Agency Research Grant

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Instem plc to Report Fiscal Year 2021 Results on Apr 26, 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director exercised options and sold UK£298k worth of stock

Instem plc Provides Revenue Guidance for the Year Ended 31 December 2021

Instem plc (LON:INS) Shares Could Be 45% Below Their Intrinsic Value Estimate

Instem plc Announces the Release of the Latest Edition of Its Leadscope Model Applier Computational Toxicology Software Solution

First half 2021 earnings released: EPS UK£0.048 (vs UK£0.095 in 1H 2020)

Instem plc's (LON:INS) Intrinsic Value Is Potentially 44% Above Its Share Price

Instem plc (AIM:INS) acquired PDS Pathology Data Systems Ltd. for CHF 14.2 million.

Instem plc (AIM:INS) acquired PDS Pathology Data Systems Ltd for CHF 14.2 million.

Full year 2020 earnings released: EPS UK£0.12 (vs UK£0.057 loss in FY 2019)

Instem plc (AIM:INS) acquired The Edge Software Consultancy Ltd. for £8.5 million.

Is Instem plc's (LON:INS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

New 90-day high: UK£5.20

Shareholders Are Thrilled That The Instem (LON:INS) Share Price Increased 190%

New 90-day high: UK£5.08

Calculating The Intrinsic Value Of Instem plc (LON:INS)

Instem plc Provides New Business Update

Instem Launches in Silico Toxicology Service

New 90-day low: UK£4.40

First half earnings released

New 90-day high - UK£5.45

Instem plc has completed a Follow-on Equity Offering in the amount of £15.750002 million.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen